Bøger af Oliver Gassmann

A strong business model is the bedrock to business success. But all too often we fail to adapt, clinging to outdated models that are no longer delivering the results we need. The brains behind The Business Model Navigator have discovered that just 55 business models are responsible for 90% of the world's most successful businesses. These 55 models from the Add-On model used by Ryanair to the Subscription model used by Spotify provide the blueprints you need to revolutionise your business and drive powerful change. As well as providing a practical framework for adapting and innovating your business model, this book also includes each of the 55 models in a quick-read format that covers: What it is Who invented it and who uses it now When and how to apply itAn excellent toolkit for developing your business model.Dr Heinz Derenbach, CEO, Bosch Software Innovations

Transforming cities through digital innovations is becoming an imperative for every city. However, city ecosystems widely struggle to start, manage and execute the transformation. This book aims to give a comprehensive overview of all facets of the Smart City transformation and provides concrete tools, checklists, and guiding frameworks.

Presenting a broad literature review of scholarly work in the area of Business Model Innovation, this new book analyses 50 management theories in the context of BMI to yield valuable new insights.

What are the secrets of competitive R&D on a global scale? Based on research with hundreds of R&D executives from more than 80 companies and 1000 R&D laboratories, this work presents fresh concepts and trends in global R&D management. It also includes case studies from 22 best-practice companies that show how to put these concepts into practice.

This book focuses on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of internationalisation, such as outside-in innovation in the early phases of R&D.

This book aids managers dealing with innovation in China, offering concrete advice on how Western firms can benefit, even in a climate of insufficient protection of intellectual property. Includes helpful examples and checklists for decision makers.

Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade.

Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade.